Targeting the cGAS-STING Pathway in Gastrointestinal Cancers: Modulating Tumor-associated Inflammation for...

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Gastrointestinal (GI) tumors are a major cause of cancer mortality, necessitating new therapeutic strategies.
• The cGAS-STING pathway, a cytosolic DNA sensor, has dual roles: enhancing anti-tumor immunity and promoting immune suppression within the tumor microenvironment.

Purpose of the Study:

• To review preclinical and clinical evidence on cGAS-STING signaling in GI cancers.
• To explore therapeutic strategies targeting the cGAS-STING pathway for improved cancer treatment.

Main Methods:

• Integration of preclinical and clinical data on cGAS-STING pathway in GI cancers.
• Emphasis on therapeutic strategies: STING agonists, immune checkpoint combinations, nanoparticle delivery, and pathway interactions.
• Analysis of interactions with DNA damage response, autophagy, and immune surveillance.

Main Results:

• cGAS-STING activation can enhance immune surveillance and therapeutic efficacy.
• Sustained activation may promote tumor growth through immune evasion and chronic inflammation.
• Preclinical studies show promise for STING agonists and combination therapies; early clinical trials show constrained but optimistic results.

Conclusions:

• Balancing the dual effects of cGAS-STING is crucial for therapeutic success.
• Biomarker-guided development, rational combinations, and advanced delivery systems are needed.
• AI-powered predictive models can personalize treatment strategies for GI cancer patients.